PREDICTION OF EFFICACY OF CANCER-TARGETED THERAPEUTIC AGENT ON BASIS OF TRIPLE QUADRUPOLE MULTIPLE REACTION MONITORING

摘要

The present invention relates to a method for predicting the reactivity of a cancer-targeted therapeutic agent, in which various types of target proteins targeted by a cancer-targeted therapeutic agent are simultaneously quantified through triple quadrupole mass spectrometry. The inventors of the present invention carefully selected peptide sequences with high selectivity in nanoflow liquid chromatography-triple quadrupole mass spectrometry, in response to clinical needs, and optimized peptide combinations and experimental conditions to enable multiple peptide quantification. As a result, validated predictive markers which can be used in cancer treatment or clinical trials, such as HER2, FGFR2, EGFR, MET, and PD-L1, and novel immunotherapy efficacy predictors (TAP2, I23O1 (IDO1), SYWC (WARS1), and UB2L6 (UBE2L6)) identified by the inventors of the present invention, can be quantified at the protein level simultaneously with multiple housekeeping control peptides, and can be applied to pre-treatment cancer tissue samples to predict the therapeutic effect of a targeted therapeutic agent.